Narcolepsy Drugs Market - Global Forecast 2026-2032

The narcolepsy drugs market is in a pivotal period of clinical advancement and operational transformation, reshaping how therapies are brought to patients worldwide. Stakeholders face evolving therapeutic standards, stringent supply dynamics, and strategic challenges as treatment options diversify and regulatory expectations increase.

Market Snapshot: Narcolepsy Drugs Market Growth

The narcolepsy drugs market expanded from USD 3.51 billion in 2025 to USD 3.76 billion in 2026 and is projected to continue growing at a CAGR of 6.79%, reaching USD 5.57 billion by 2032. This sustained growth underscores shifting industry priorities, with therapeutic innovation, personalized care pathways, and intensified commercial development underpinning a dynamic competitive environment.

Scope & Segmentation

Drug Classes: Amphetamine Salts, Modafinil Derivatives (Modafinil, Armodafinil), Novel Agents (Pitolisant, Solriamfetol), and Sodium Oxybate—mechanism-level distinctions guide clinical adoption and payer strategy.
Distribution Channels: Hospital pharmacy, online pharmacy, and retail pharmacy each shape patient convenience, adherence, and authorization workflows.
Formulation Types: Capsules, solutions, and tablets influence treatment adherence, dosing practices, and innovation potential, such as once-nightly options.
End-User Contexts: Home use, hospitals, and sleep clinics reflect varying access patterns, monitoring capabilities, and clinical management requirements.
Regions: Americas, Europe, Middle East & Africa, and Asia-Pacific, each with distinct policy and healthcare infrastructure influencing market access and rollout strategies.
Technologies & Commercial Models: Integration of digital health adjuncts, comparative effectiveness frameworks, and remote monitoring solutions supports data-driven decision-making and lifecycle management.

Key Takeaways: Strategic Insights for Decision-Makers

Therapeutic innovation is broadening prescriber options, with new wake-promoting agents and histaminergic modulators supplementing established treatments.
Formulation science has become central as dosing convenience and long-term safety impact patient adherence and product differentiation.
Personalized treatment and evolving care pathways drive more multidisciplinary coordination in sleep clinics and health systems, improving patient management strategies.
Manufacturers are increasingly leveraging partnerships, digital platforms, and contract services to support rapid product introductions and manage controlled substances.
Supply chain optimization is critical, with active pharmaceutical ingredient sourcing, inventory strategies, and risk mitigation efforts focusing on ensuring resilience and continuity.
Regional policies and payer environments require tailored commercialization planning, especially where reimbursement and diagnostic infrastructure vary considerably between markets.

Tariff Impact: Navigating Supply Chain and Pricing Dynamics

Anticipated tariff changes in the US are introducing operational complexity for organizations depending on cross-border supply of active pharmaceutical ingredients and finished products. Increased duties elevate production and procurement costs, pressuring manufacturer margins and prompting new supplier contracts or price adjustments. Companies are diversifying sourcing, considering domestic manufacturing, and reassessing inventory models to limit exposure to supply disruptions. Regulatory compliance is also impacted, requiring updated filings and enhanced validation activities when sourcing patterns shift. These factors drive new engagement strategies with payers, as well as innovative contracting and patient support models to maintain access and commercial viability under changing cost structures.

Methodology & Data Sources

This research integrates primary interviews with neurologists, sleep specialists, pharmacists, payer leaders, and supply chain executives. It incorporates peer-reviewed clinical studies, regulatory filings, and operational scenario analysis to triangulate data across the entire narcolepsy therapy landscape. Analytical techniques focus on reconciling clinical trial endpoints with real-world effectiveness, and scenario modeling highlights operational sensitivities and constraints.

Why This Report Matters

Supports targeted R&D, investment, and commercialization choices across global and regional markets.
Provides actionable insight into clinical, operational, and regulatory trends to inform portfolio planning and supply strategy.

Conclusion

Integrated evidence generation, robust supply chain planning, and patient-centered strategies are essential for lasting commercial success. Decision-makers can leverage these insights to adapt proactively and sustain market advantage as the narcolepsy treatment landscape evolves.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Narcolepsy Drugs Market, by Drug Class

8.1. Amphetamine Salts
8.2. Modafinil Derivatives
8.2.1. Armodafinil
8.2.2. Modafinil
8.3. Novel Agents
8.3.1. Pitolisant
8.3.2. Solriamfetol
8.4. Sodium Oxybate

9. Narcolepsy Drugs Market, by Distribution Channel

9.1. Hospital Pharmacy
9.2. Online Pharmacy
9.3. Retail Pharmacy

10. Narcolepsy Drugs Market, by Formulation

10.1. Capsules
10.2. Solution
10.3. Tablets

11. Narcolepsy Drugs Market, by End User

11.1. Home Use
11.2. Hospitals
11.3. Sleep Clinics

12. Narcolepsy Drugs Market, by Region

12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific

13. Narcolepsy Drugs Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Narcolepsy Drugs Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. United States Narcolepsy Drugs Market
16. China Narcolepsy Drugs Market

17. Competitive Landscape

17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Amneal Pharmaceuticals LLC
17.6. Aurobindo Pharma Limited
17.7. Avadel Pharmaceuticals plc
17.8. Axsome Therapeutics, Inc.
17.9. Biogen Inc.
17.10. Bioprojet SCR
17.11. Dr. Reddy’s Laboratories Limited
17.12. Eisai Co., Ltd.
17.13. Harmony Biosciences Holdings, Inc.
17.14. Hikma Pharmaceuticals PLC
17.15. Jazz Pharmaceuticals plc
17.16. Ligand Pharmaceuticals Incorporated
17.17. Lupin Limited
17.18. Novartis AG
17.19. Otsuka Pharmaceutical Co., Ltd.
17.20. Pfizer Inc.
17.21. Sanofi S.A.
17.22. Sun Pharmaceutical Industries Limited
17.23. Takeda Pharmaceutical Company Limited
17.24. Teva Pharmaceutical Industries Limited
17.25. UCB S.A.
17.26. Viatris Inc.

List of Figures

FIGURE 1. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL NARCOLEPSY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL NARCOLEPSY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY AMPHETAMINE SALTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY AMPHETAMINE SALTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY AMPHETAMINE SALTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY ARMODAFINIL, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY ARMODAFINIL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY ARMODAFINIL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY PITOLISANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY PITOLISANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY PITOLISANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SOLRIAMFETOL, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SOLRIAMFETOL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SOLRIAMFETOL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SODIUM OXYBATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SODIUM OXYBATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SODIUM OXYBATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY HOME USE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY HOME USE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY HOME USE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SLEEP CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SLEEP CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY SLEEP CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 61. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 62. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 63. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 64. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 65. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 66. AMERICAS NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 67. NORTH AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. NORTH AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 69. NORTH AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 70. NORTH AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 71. NORTH AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 72. NORTH AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 74. LATIN AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. LATIN AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 76. LATIN AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 77. LATIN AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 78. LATIN AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 79. LATIN AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 88. EUROPE NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. EUROPE NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 90. EUROPE NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 91. EUROPE NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 92. EUROPE NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 93. EUROPE NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 94. EUROPE NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. MIDDLE EAST NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. MIDDLE EAST NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 97. MIDDLE EAST NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 98. MIDDLE EAST NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 99. MIDDLE EAST NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 100. MIDDLE EAST NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 102. AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 104. AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 105. AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 106. AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 108. AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. ASEAN NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. ASEAN NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 119. ASEAN NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 120. ASEAN NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 121. ASEAN NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. ASEAN NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 123. ASEAN NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. GCC NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GCC NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 126. GCC NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 127. GCC NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 128. GCC NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 129. GCC NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 130. GCC NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. EUROPEAN UNION NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. BRICS NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. BRICS NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 140. BRICS NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 141. BRICS NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 142. BRICS NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. BRICS NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 144. BRICS NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 145. G7 NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. G7 NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 147. G7 NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 148. G7 NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 149. G7 NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 150. G7 NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 151. G7 NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. NATO NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. NATO NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 154. NATO NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 155. NATO NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 156. NATO NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 157. NATO NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 158. NATO NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 161. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 162. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 163. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 164. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 165. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 166. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. CHINA NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 168. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 169. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 170. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
TABLE 171. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 172. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 173. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Narcolepsy Drugs market report include:

Amneal Pharmaceuticals LLC
Aurobindo Pharma Limited
Avadel Pharmaceuticals plc
Axsome Therapeutics, Inc.
Biogen Inc.
Bioprojet SCR
Dr. Reddy’s Laboratories Limited
Eisai Co., Ltd.
Harmony Biosciences Holdings, Inc.
Hikma Pharmaceuticals PLC
Jazz Pharmaceuticals plc
Ligand Pharmaceuticals Incorporated
Lupin Limited
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Pfizer Inc.
Sanofi S.A.
Sun Pharmaceutical Industries Limited
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited
UCB S.A.
Viatris Inc.

Table Information

Report Attribute	Details
No. of Pages	194
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 3.76 Billion
Forecasted Market Value ( USD ) by 2032	$ 5.57 Billion
Compound Annual Growth Rate	6.7%
Regions Covered	Global
No. of Companies Mentioned	23

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3513EUR$3,939USD£3,047GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3789EUR$4,249USD£3,286GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5136EUR$5,759USD£4,454GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6215EUR$6,969USD£5,390GBP

Market Snapshot: Narcolepsy Drugs Market Growth

Scope & Segmentation

Key Takeaways: Strategic Insights for Decision-Makers

Tariff Impact: Navigating Supply Chain and Pricing Dynamics

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Narcolepsy Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

Narcolepsy Drugs Market Report 2025

Narcolepsy Drugs Market Report by Type, Disease Type, Therapeutic Type, and Region 2025-2033

Narcolepsy: Market View

United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 2033 - 7.88% CAGR Driven by Novel Therapies and Better Diagnosis